Comparative Pharmacology
Head-to-head clinical analysis: FOAMCOAT versus MAFENIDE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMCOAT versus MAFENIDE ACETATE.
FOAMCOAT vs MAFENIDE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
Mafenide acetate is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competitively antagonizing para-aminobenzoic acid (PABA), thereby preventing bacterial growth. It has broad-spectrum activity against gram-negative and gram-positive organisms, including Pseudomonas aeruginosa.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
Apply topically as a thin layer to affected areas once or twice daily. The dosage form is an 11.1% cream or solution. The cream is applied using a sterile gloved hand; the solution is applied with a sterile spray or brush.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Approximately 45 minutes (range 30-60 minutes) for the parent compound; the metabolite p-CBS has a longer half-life of about 4 hours.
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Renal: approximately 80% excreted unchanged in urine; the remainder is metabolized to p-carboxybenzene sulfonamide (p-CBS) which is also renally excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic